JP2009526043A - バニロイド受容体１に関連する状態を治療するための新規のスピロ［イミダゾリジン−４，３’−インドール］−２，２”，５’（ｉｈ）−トリオン - Google Patents

バニロイド受容体１に関連する状態を治療するための新規のスピロ［イミダゾリジン−４，３’−インドール］−２，２”，５’（ｉｈ）−トリオン Download PDF

Info

Publication number
JP2009526043A
JP2009526043A JP2008554186A JP2008554186A JP2009526043A JP 2009526043 A JP2009526043 A JP 2009526043A JP 2008554186 A JP2008554186 A JP 2008554186A JP 2008554186 A JP2008554186 A JP 2008554186A JP 2009526043 A JP2009526043 A JP 2009526043A
Authority
JP
Japan
Prior art keywords
pain
salt
medicament
compound
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008554186A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009526043A5 (enExample
Inventor
カルメン・レオン
ミロスラウ・トーマセウスキ
サイモン・ウー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38345567&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2009526043(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2009526043A publication Critical patent/JP2009526043A/ja
Publication of JP2009526043A5 publication Critical patent/JP2009526043A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
JP2008554186A 2006-02-07 2007-02-06 バニロイド受容体１に関連する状態を治療するための新規のスピロ［イミダゾリジン−４，３’−インドール］−２，２”，５’（ｉｈ）−トリオン Pending JP2009526043A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77111906P 2006-02-07 2006-02-07
PCT/SE2007/000107 WO2007091947A2 (en) 2006-02-07 2007-02-06 Novel spiro[imidazolidine-4,3'-indole]-2,2',5(1'h)-triones for treatment of conditions associated with vanilloid receptor 1

Publications (2)

Publication Number Publication Date
JP2009526043A true JP2009526043A (ja) 2009-07-16
JP2009526043A5 JP2009526043A5 (enExample) 2010-03-11

Family

ID=38345567

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008554186A Pending JP2009526043A (ja) 2006-02-07 2007-02-06 バニロイド受容体１に関連する状態を治療するための新規のスピロ［イミダゾリジン−４，３’−インドール］−２，２”，５’（ｉｈ）−トリオン

Country Status (21)

Country Link
US (2) US20070185179A1 (enExample)
EP (1) EP2013215A4 (enExample)
JP (1) JP2009526043A (enExample)
KR (1) KR20080094906A (enExample)
CN (1) CN101415711A (enExample)
AR (1) AR059265A1 (enExample)
AU (1) AU2007212786B2 (enExample)
BR (1) BRPI0707423A2 (enExample)
CA (1) CA2641632A1 (enExample)
CL (1) CL2009000523A1 (enExample)
IL (1) IL192890A0 (enExample)
NO (1) NO20083547L (enExample)
NZ (1) NZ571070A (enExample)
RU (1) RU2421457C2 (enExample)
SA (1) SA07280027B1 (enExample)
SG (1) SG169387A1 (enExample)
TW (1) TW200801011A (enExample)
UA (1) UA93226C2 (enExample)
UY (1) UY30132A1 (enExample)
WO (1) WO2007091947A2 (enExample)
ZA (1) ZA200806407B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013057944A1 (ja) * 2011-10-19 2013-04-25 興和株式会社 新規なスピロインドリン化合物、及びそれを含有する医薬

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI586668B (zh) * 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
CN108409746B (zh) * 2018-05-15 2021-08-24 中山大学 一种含吡咯或吲哚并氮杂环烷结构的手性氧代螺环吲哚类化合物及其消旋体和制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5683491A (en) * 1979-11-13 1981-07-08 Ici Ltd 1**substituteddspiro*imidazolidinee4*3**indoline** 2*2**55tirone* its manufacture and medicine containing it and controlling aldose reductase
JPS57192385A (en) * 1981-05-12 1982-11-26 Ici Ltd Non-toxic biodegradable 1'-substituted- spiro(imidazolidine-4,3'-indoline)-2,2',5- trione derivative, manufacture and pharmaceutical for treating or preventing diabetes or complication of galactosemia

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4490381A (en) * 1979-11-13 1984-12-25 Imperial Chemical Industries Plc 1'-Substituted spiro[imidazolidine-4,3'-indoline]2,2',5-triones
GB8331194D0 (en) 1982-12-20 1983-12-29 Ici Plc Chemical process
US4611062A (en) * 1984-03-26 1986-09-09 Imperial Chemical Industries Plc Process for resolving certain spiro compounds
WO1992007830A2 (en) 1990-10-29 1992-05-14 Pfizer Inc. Oxindole peptide antagonists
JP2003505388A (ja) * 1999-07-21 2003-02-12 アストラゼネカ・アクチエボラーグ 新規化合物
US7248802B2 (en) 2002-11-27 2007-07-24 Nokia Corporation Distribution of a synchronization signal in an optical communication system
TW200508197A (en) 2003-03-31 2005-03-01 Ucb Sa Indolone-acetamide derivatives, processes for preparing them and their uses
SE0301446D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
AU2004247559B2 (en) 2003-06-12 2009-08-27 Astellas Pharma Inc. Benzamide derivative or salt thereof
GB0326633D0 (en) * 2003-11-14 2003-12-17 Merck Sharp & Dohme Therapeutic agents
JP2008508190A (ja) 2004-07-19 2008-03-21 ノボ ノルディスク アクティーゼルスカブ 肥満または肥満に関連する疾患および障害の治療におけるカプサイシン受容体の活性の阻害
WO2007091948A2 (en) 2006-02-07 2007-08-16 Astrazeneca Ab Novel spiro [imidazolidine-4, 3´-indole] 2, 2´,5´(1h) triones for treatment of conditions associated with vanilloid receptor 1

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5683491A (en) * 1979-11-13 1981-07-08 Ici Ltd 1**substituteddspiro*imidazolidinee4*3**indoline** 2*2**55tirone* its manufacture and medicine containing it and controlling aldose reductase
JPS57192385A (en) * 1981-05-12 1982-11-26 Ici Ltd Non-toxic biodegradable 1'-substituted- spiro(imidazolidine-4,3'-indoline)-2,2',5- trione derivative, manufacture and pharmaceutical for treating or preventing diabetes or complication of galactosemia

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013057944A1 (ja) * 2011-10-19 2013-04-25 興和株式会社 新規なスピロインドリン化合物、及びそれを含有する医薬
US8921576B2 (en) 2011-10-19 2014-12-30 Kowa Company, Ltd. Spiroindoline compound, and medicinal agent comprising same

Also Published As

Publication number Publication date
AR059265A1 (es) 2008-03-19
AU2007212786B2 (en) 2011-06-02
WO2007091947A3 (en) 2007-10-04
US7868181B2 (en) 2011-01-11
IL192890A0 (en) 2009-02-11
EP2013215A4 (en) 2010-09-08
UA93226C2 (en) 2011-01-25
EP2013215A2 (en) 2009-01-14
KR20080094906A (ko) 2008-10-27
AU2007212786A1 (en) 2007-08-16
ZA200806407B (en) 2009-04-29
BRPI0707423A2 (pt) 2011-05-03
TW200801011A (en) 2008-01-01
NZ571070A (en) 2011-07-29
US20090137650A1 (en) 2009-05-28
WO2007091947A2 (en) 2007-08-16
UY30132A1 (es) 2009-07-17
CA2641632A1 (en) 2007-08-16
SG169387A1 (en) 2011-03-30
RU2421457C2 (ru) 2011-06-20
CN101415711A (zh) 2009-04-22
SA07280027B1 (ar) 2010-11-22
RU2008131905A (ru) 2010-03-20
NO20083547L (no) 2008-11-05
CL2009000523A1 (es) 2009-07-17
US20070185179A1 (en) 2007-08-09
AU2007212786A8 (en) 2010-05-06
WO2007091947A8 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
JP5057273B2 (ja) イソインドリン−１−ワン誘導体
JP2022513592A (ja) ビフェニル系化合物、その中間体、製造方法、医薬組成物及び使用
JP4667384B2 (ja) イオンチャネルリガンドとしてのアミド誘導体および薬学的組成物、ならびにこれらを使用する方法
EA019068B1 (ru) Соединение 3-аминокарбазола, фармацевтическая композиция, его содержащая, и способ их получения
JP2009538358A (ja) 脂肪酸アミド加水分解酵素のオキサゾリルピペリジン・モジュレーター
AU2007233035A1 (en) Substituted bicyclic derivative and use thereof
CA2659952A1 (en) 8-hydroxyquinoline compounds and methods thereof
JP2023553291A (ja) Ｔｒｐｍ３媒介性障害を治療するためのアリール誘導体
JP2009521431A (ja) バニロイド受容体１（ｖｒ１）阻害剤としての新規なベンゾイミダゾール誘導体
US7868181B2 (en) Compounds
CN112888674A (zh) 多环化合物作为可溶性环氧化物水解酶抑制剂
WO2005016881A1 (de) Bicyclische indolinsulfonamid-derivate
CN116082259B (zh) 氨基甲酸酯基或氨甲酰基取代的5-ht2b拮抗剂
JPH11506425A (ja) エチニルチアゾール誘導体
TWI454470B (zh) 硫苯並薁丙酸衍生物之製造法
EA030692B1 (ru) Производные индол-3-карбинола
CN103193695B (zh) 3-苯基-3-吡咯基戊烷类衍生物及其医药用途
WO2012081570A1 (ja) ラクタム化合物又はその塩及びｐｐａｒ活性化剤
MX2008009999A (es) Novedosos espiro[imidazolidina-4,3'-indol]-2,2',5(1'4)-triones para tratamiento de condiciones asociadas con receptor 1 vaniloide
RU2155748C2 (ru) Производные циклогексадиена, смесь их изомеров или отдельные изомеры и их соли и фармацевтическая композиция с избирательным модулирующим действием на зависимые от кальция калиевые канальцы высокой проводимости
JP2005255666A (ja) ５−リポキシゲナーゼ阻害活性を有する６−アルキルアミノ−２，２’−二重置換−７，８−二重置換−２ｈ−１−ベンゾピラン誘導体
CA2578332A1 (en) Derivatives of pyrazoline, procedure for obtaining them and use thereof as therapeutic agents
JP2004518627A (ja) 置換ビフェニル誘導体、その製造方法およびそれを含有する医薬組成物
JP2009526042A (ja) バニロイド受容体１に関連する状態を治療するためのスピロ［イミダゾリジン−４，３’−インドール］２，２’，５’（１ｈ）−トリオンの使用
JP2000191663A (ja) 縮合ピリダジン誘導体の製造法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120717

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130423